MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$3,559K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable securit...
Equity-based compensation expens...
Accrued expenses and other liabi...
Others
Negative Cash Flow Breakdown
Net loss
Purchase of marketable securitie...
Accretion of discount on marketa...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-53,704
-49,661
-50,713
-50,610
Equity-based compensation expense
8,447
7,616
7,312
9,467
Accretion on marketable securities
-
-777
-931
-1,358
Accretion of discount on marketable securities
-1,331
-
-
-
Depreciation and amortization
79
79
79
79
Prepaid expenses and other assets
-2,088
662
-840
-798
Accounts payable
1,216
1,667
-879
-739
Accrued expenses and other liabilities
4,209
-4,307
6,183
5,486
Net cash used in operating activities
-38,219
-46,045
-38,109
-36,877
Maturities of marketable securities
55,250
52,549
42,000
80,000
Purchase of marketable securities
14,572
20,135
19,598
12,570
Purchase of property and equipment
-
-
11
38
Net cash provided by investing activities
40,678
32,414
22,391
67,392
Issuance of common stock under equity-based compensation plans
1,100
380
715
0
Issuance of common stock and pre-funded warrants, net of issuance costs
-
-
0
0
Acquisition of noncontrolling interests
-
-
0
0
Net cash provided by financing activities
1,100
380
715
0
Net decrease in cash and cash equivalents
3,559
-13,251
-15,003
30,515
Cash and cash equivalents at beginning of period
75,081
88,332
103,335
83,005
Cash and cash equivalents at end of period
78,640
75,081
88,332
103,335
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Maturities of marketable
securities
$55,250K
(-81.24%↓ Y/Y)
Issuance of common stock
under equity-based...
$1,100K
(194.91%↑ Y/Y)
Net cash provided by
investing activities
$40,678K
(-54.91%↓ Y/Y)
Net cash provided by
financing activities
$1,100K
(194.91%↑ Y/Y)
Canceled cashflow
$14,572K
Net decrease in cash
and cash...
$3,559K
(134.94%↑ Y/Y)
Canceled cashflow
$38,219K
Purchase of marketable
securities
$14,572K
(-92.87%↓ Y/Y)
Equity-based compensation
expense
$8,447K
(-56.14%↓ Y/Y)
Accrued expenses and
other liabilities
$4,209K
(215.54%↑ Y/Y)
Prepaid expenses and
other assets
-$2,088K
(60.30%↑ Y/Y)
Accounts payable
$1,216K
(56.10%↑ Y/Y)
Depreciation and
amortization
$79K
(-48.37%↓ Y/Y)
Net cash used in
operating activities
-$38,219K
(62.07%↑ Y/Y)
Canceled cashflow
$16,039K
Net loss
-$53,704K
(54.70%↑ Y/Y)
Accretion of discount on
marketable securities
-$1,331K
Buy us a coffee
Cullinan Therapeutics, Inc. (CGEM)
Cullinan Therapeutics, Inc. (CGEM)